Yes, some people have transitioned from taking Imbruvica (ibrutinib) to second-generation BTK inhibitors like Calquence (acalabrutinib). This can happen if they experience side effects such as dizziness or if Imbruvica is not effective for them.

Key Points
- Imbruvica (Ibrutinib): Common side effects include dizziness, Show Full Answer

Yes, some people have transitioned from taking Imbruvica (ibrutinib) to second-generation BTK inhibitors like Calquence (acalabrutinib). This can happen if they experience side effects such as dizziness or if Imbruvica is not effective for them.

Key Points:
- Imbruvica (Ibrutinib): Common side effects include dizziness, fever, fatigue, rash, muscle and bone pain, bruising, diarrhea, abnormal bleeding, and low blood cell counts. Serious side effects can include hypertension, increased risk for infections, dangerous bleeding, fetal harm, cardiac arrhythmias, and the development of other cancers.
- Calquence (Acalabrutinib): Approved for use in adults with CLL/SLL, often recommended for refractory and relapsed cases. Common side effects include headache, diarrhea, muscle and joint pain, infection, hemorrhage, and irregular heartbeat.

If you are experiencing side effects, it is important to discuss them with your doctor to determine the best course of action.

 This AI-generated response comes from MyLeukemiaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Imbruvica (Ibrutinib) for Leukemia | MyLeukemiaTeam

Oral Therapy vs. Traditional Chemotherapy for CLL/SLL | MyLeukemiaTeam